Lutetium (¹⁷⁷Lu) vipivotide tetraxetan: all 47 studies that test it

Page 1 of 1. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.

• Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate CancerNot yet recruitingNCT07860554Phase 2
• Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO TrialRecruitingNCT07698535Phase 2
• Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate CancerNot yet recruitingNCT07682649Phase 1
• Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE TrialRecruitingNCT07650240Phase 2
• A Study of 177Lu-PSMA-617 in People With GliomasRecruitingNCT07223034Phase 1
• Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate AdenocarcinomaRecruitingNCT07150715Phase 2
• 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate CancerRecruitingNCT07145177Phase 1
• Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617RecruitingNCT07054346Phase 1
• Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617RecruitingNCT06972628Phase 2
• Lu-177 PSMA Treatment in Cell Renal CarcinomaNot yet recruitingNCT06959433Phase 3
• Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)RecruitingNCT06943495Phase 1
• Radiopharmaceutical Treatment of Advanced Kidney CancerRecruitingNCT06783348Phase 2
• Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate CancerRecruitingNCT06738303Phase 2
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingNCT06632977Phase 2
• STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate CancerRecruitingNCT06574880Phase 1/2
• Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing DiseaseRecruitingNCT06526299Phase 2
• Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)RecruitingNCT06496581Phase 3
• 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate CancerRecruitingNCT06449781Phase 2
• Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA TrialRecruitingNCT06288113Phase 2
• Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)RecruitingNCT06216249Phase 2
• Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate CancerRecruitingNCT06145633Phase 2
• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.RecruitingNCT05939414Phase 3
• Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate CancerRecruitingNCT05803941Phase 4
• Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate CancerRecruitingNCT05766371Phase 2
• Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerRecruitingNCT05113537Phase 1/2
• 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate CancerActive, not recruitingNCT04689828Phase 3Results posted
• 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT03805594Phase 1Results posted
• 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPCTerminatedNCT03545165Phase 1/2Results posted
• Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate CancerCompletedNCT03511664Phase 3Results posted
• Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPCCompletedNCT03042468Phase 1/2Results posted
• Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapyTerminatedNCT03042312Phase 2Results posted
• 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and CytopeniaWithdrawnNCT07025512Phase 2
• 177LuPSMA in Renal Cell CarcinomaActive, not recruitingNCT06964958Phase 2
• A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) StudyActive, not recruitingNCT06531499Phase 1
• 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate CancerWithdrawnNCT06329830Phase 1/2
• LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate CancerActive, not recruitingNCT06303713Phase 1
• The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical TrialWithdrawnNCT06199453Phase 2
• Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal FunctionActive, not recruitingNCT06004661Phase 2
• Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT05340374Phase 1/2
• EBRT + Lu-PSMA for N1M0 Prostate CancerCompletedNCT05162573Phase 1
• A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate CancerActive, not recruitingNCT05079698Phase 1
• An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)Active, not recruitingNCT04720157Phase 3
• 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate CancerActive, not recruitingNCT04663997Phase 2
• Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate CancerCompletedNCT04443062Phase 2
• Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to ProstatectomyActive, not recruitingNCT04430192Phase 1/2
• In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to ChemotherapyActive, not recruitingNCT04343885Phase 2
• Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate CancerCompletedNCT03828838Phase 1/2

← Lutetium (¹⁷⁷Lu) vipivotide tetraxetan overview